Tuesday, 17 November 2026Follow on 𝕏
Policy

House inquiry probes whether PBMs targeted pharmacies with audits after reform push

A congressional inquiry is examining whether independent pharmacies faced retaliatory audits from the largest pharmacy benefit managers after publicly backing industry reform. Audits were designed as a legitimate safeguard for drug benefits, but they consume time and resources from pharmacists who should be treating patients.

James Comer, the Kentucky Republican who chairs the House Oversight and Government Reform Committee, requested records and briefings in October from CVS Caremark (CVS), Express Scripts (CI) and Optum Rx (UNH). The inquiry follows pharmacy support for H.R. 6610, the Pharmacists Fight Back in Federal Employee Health Benefit Plans Act. The claims remain allegations, but they amplify complaints independent pharmacies have voiced for years.

The letters raise distinct concerns for each company. The Caremark letter cites audit notices over small prescription charges that allegedly arrived after their stated compliance deadlines. The Express Scripts letter points to closely spaced notices from several PBMs, and deadlines that passed before the notices were received. The Optum Rx letter describes pharmacies that received a first audit notice and then two further audits in quick succession.

The committee wants audit selection methods, training materials, provider agreements and nationwide audit totals for independent pharmacies, broken down by affiliation. It has also asked for detailed audit records for independent pharmacies in Kentucky, Mississippi and Florida. Staff briefings were requested by October 30, with documents due by November 6.

The material could help separate routine compliance activity from selective treatment. Timing alone cannot establish retaliation, but selection criteria, the experience of comparable pharmacies, internal communications and documented compliance concerns would give investigators a firmer basis.

Benefit plans have valid reasons to confirm that billed prescriptions were dispensed, that records support claims and that contract terms were met. PBM provider manuals typically cast their audit programs as tools against fraud, waste and abuse. Yet scrutiny cuts both ways: a New York State Comptroller report in October found Caremark failed to carry out certain contractually required pharmacy audits for the state’s Empire Plan. The comptroller urged stronger audit selection and clearer duties for identifying and referring suspected fraud.

The policy challenge is to preserve meaningful oversight while ensuring audit authority is applied consistently and fairly. Even legitimate audits must comply with the law on selection, scope, deadlines and financial consequences.

For an independent pharmacy, responding can be draining, requiring staff to pull prescription records, invoices, delivery logs and correspondence while keeping the business running. Even when no repayment follows, the response carries a cost.

H.R. 6610 targets PBM practices in the Federal Employees Health Benefits Program. The committee advanced the bill, as amended, by a 40-2 vote in July. The substitute text would tie pharmacy reimbursement to acquisition-cost benchmarks, add a capped percentage payment and a dispensing fee based on state Medicaid rates, set rebate requirements and restrict steering and certain reimbursement cuts.

The audit inquiry raises a separate question: whether pharmacies can join the policy debate without facing adverse treatment. A credible reform process depends on lawmakers hearing from the businesses and clinicians most affected by current practices, free of the threat of retaliation.

More news

All news →